ALSUntangled Update 1: Investigating a bug (Lyme Disease) and a drug (Iplex) on behalf of people with ALS

Amyotrophic Lateral Sclerosis

Volumn 10, Issue 4, 2009, Pages 248-250

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

MECASERMIN RINFABATE; PLACEBO; SOMATOMEDIN C;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CHOLELITHIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIENCE; HEART ARREST; HUMAN; INFECTION; LYME DISEASE; MYOCLONUS; PRIORITY JOURNAL; TREATMENT RESPONSE; WESTERN BLOTTING;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LYME DISEASE;

EID: 70249127223     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/17482960903208599     Document Type: Article

References (16)

1. Bedlack RS, Hardiman O. ALSUntangled (ALSU): A scientific approach to off-label treatment options for people with ALS using tweets and twitters. ALS. 2009;10:1290130.
2. Samento.com.ec [home page on the internet]. The website for the herbal supplement Samento; 2009 [cited July 26, 2009]. Nutranews section [1 page]. Available from http://www.samento.com.ec/nutranews/ story002.html.
3. Chroniclymedisease.com. The website of the chroniclymedisesae. com team; 2009 [cited July 26, 2009]. Main section [1 page]. Available from http://www.chroniclymedisease.com/
4. Harvey WT, Martz D. Motor neuron disease recovery associated with IV ceftriaxone and anti-Babesia therapy. Acta Neurol Scand. 2007;115:129-31.
5. Halperin J, Kaplan G, Brazinsky S, Tsai T, Cheng T, Ironside A, et al. Immunologic Reactivity Against Borrelia burgdorferi in Patients With Motor Neuron Disease. Arch Neurol. 1990;47(5):586-94.
6. Waisbren B, Cashman N, Schell R, Johnson R. Borrelia burgdorferi antibodies and amyotrophic lateral sclerosis. Lancet. 1987;2(8554):332-3.
7. Halperin J, Logigian E, Finkel M, Pearl R. Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Neurology. 1996;46: 619-27.
8. CDC. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease; 1995.
9. Murphree B, Kugeler K, Mead P. Surveillance for lyme disease - United States 1999 to 2006: Center for Disease Control (CDC); 2008.
10. Halperin J, Shapiro E, Logigian E, et. al. Practice parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the quality standards subcommittee of the American academy of neurology. Neurology 2007;69:91-102.
11. Insmed.com [home page on the internet]. Richmond: Insmed Incorporated; 2008 [cited 2009 July 24]. Available from: http://www.insmed.com/iplex.php.
12. Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et. al. Effect of recombinant human insulin-like growth factor-1 on progression of ALS. A placebo-controlled study. The North American ALS/IGF-1 Study Group. Neurology 1997:49(6):1621-1630.
13. Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et. al. A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis. European ALS/IGF-1 Study Group. Neurology 1998;51(2):583-586.
14. Sorenson EJ, Windbank AJ, Madrekar JN, Bamlet WR, Appel SH, Armon C, et. al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 2008;71(22): 1770-1775.
15. Williams RM, McDonald A, O'Savage M, Dunger DB. Mecasermin rinfabate: rhIGF-1/rhIGFBP-3 complex: IPLEX. Expert Opin Drug Metab Toxicol. 2008;4(3): 311-324.
16. Wfnals.org [home page on the internet]. The website of the world federation of neurology research group on ALS; 2009 [cited July 26, 2009]. ALSU section [1 page]. Available from www.wfnals.org.